Baricitinib reduces mortality risk in patients hospitalized with COVID-19
1. Baricitinib with usual care was associated with a 13% proportional reduction in mortality compared to treatment as usual care ...
Tag: JAK1/2 inhibitor
#VisualAbstract: Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...
Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy. 2. ...